01 Oct
A large percentage of patients with gastrointestinal tumors (such as pancreatic, liver, gastric, colorectal tumors) and some other malignancies have been shown to have elevated serum or plasma CA 19-9 levels. The serum or plasma CA 19-9 levels may be useful for monitoring disease activity predicting relapse following treatment. CA 19-9 should not be used as a screening test.